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Abstract: The advantages offered by centrifugal microfluidic systems have encouraged its rapid
adaptation in the fields of in vitro diagnostics, clinical chemistry, immunoassays, and nucleic
acid tests. Centrifugal microfluidic devices are currently used in both clinical and point-of-care
settings. Recent studies have shown that this new diagnostic platform could be potentially used in
extreme point-of-care settings like remote villages in the Indian subcontinent and in Africa. Several
technological inventions have decentralized diagnostics in developing countries; however, very few
microfluidic technologies have been successful in meeting the demand. By identifying the finest
difference between the point-of-care testing and extreme point-of-care infrastructure, this review
captures the evolving diagnostic needs of developing countries paired with infrastructural challenges
with technological hurdles to healthcare delivery in extreme point-of-care settings. In particular, the
requirements for making centrifugal diagnostic devices viable in developing countries are discussed
based on a detailed analysis of the demands in different clinical settings including the distinctive
needs of extreme point-of-care settings.
Keywords: diagnostics; centrifugal microfluidics; point-of-care; developing countries; clinical
chemistry; immunoassays; nucleic acid tests
1. Introduction
Centrifugal force-based systems have been used in various biological applications for many
years, with the most modern form of this simple technology used even today in clinical laboratories.
Centrifugal microfluidic technology combines the benefits of both microfluidics and centrifugal forces
in a single device. Rotating the microfluidic disc at various spinning rates induces three different forces
on the disc: centrifugal, Coriolis, and Euler forces, each of which can be applied to various microfluidic
device operations in an automated manner [1–3].
Centrifugal microfluidic technology has been identified as a strong candidate for point-of-care
in vitro diagnostics (IVD) and has achieved significant commercial success [3,4]. Major multinationals
such as Roche and 3M, among others, offer commercial products based on this technology. IVD
procedures include clinical chemistry, immunoassays for protein detection, and nucleic acid testing for
molecular detection [5]. These IVD procedures involve complex biological assays that usually require
a sequence of steps, including sample preparation, incubation, washing, etc. All of these steps can be
integrated onto a single disc in a centrifugal microfluidic device [4]. The device’s motor can also be
programmed to adopt multiple fluid spinning profiles for specific applications. This ensures that the
entire device remains compact. Most commercially available centrifugal microfluidic devices have a
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small footprint and operate as simple sample-to-answer micro-total analytical systems (µTASs). When
compared to other microfluidic technologies, centrifugal microfluidic technology has demonstrated
many advantages like eliminating the need for multiple pumps, capability to process samples with a
wide range of volume and to have pre-stored reagents, and simple and robust operation, which make
the centrifugal microfluidic technology suitable for applications in point-of-care testing (POCT).
Extreme point of care testing (EPOCT) is POCT performed in an unfavorable environment
characterized by a lack of basic infrastructure such as clean water, dust-free air and surfaces, stable
temperatures, uninterrupted power supplies, and other conditions that are the basic requirements
for the operation of existing POCT devices [6]. Despite significant advancements achieved in POCT
devices, centrifugal microfluidics technology has not yet been considered for use in EPOCT devices.
Present diagnostic tools used in EPOCT are limited to lateral flow strips (LFSs); it is comprised of
capture molecules and nanoparticle functionalized on a nitrocellulose membrane that are housed inside
a protective plastic casing [7]. LFSs are used both in POCT and EPOCT because of their reasonable
cost, easy usage, rapid tests, acceptable sensitivity, and availability for a wide range of diseases [8,9].
Currently, LFSs are widely used for disease screening, including for human immunodeficiency virus
(HIV), malaria, tuberculosis, and hepatitis C, and for epidemiology surveillance in cases such as
Ebola [8,10]. Although LFSs have aided faster clinical decisions in many disease screening applications,
they cannot perform advanced bioassays to answer more complex biomedical questions [9–12]. For
example, drug resistant types of malarial strains have been diagnosed in large groups of people among
African populations, and these malarial strains can easily escape the detection based on the current
LFS test, perpetuating life-threatening conditions [13,14].
Further development of the diagnostic tools for EPOCT has been a focus for various research
groups in recent years [15]. Revolutionary technologies like microfluidic paper-based analytic devices
(µPAD)s [16], multiplexed 2D paper devices [17], and mobile phone-based technologies [18,19] have
demonstrated their potential to work effectively in POCT and EPOCT conditions. Regardless of its
successes, LFS’s limitations still remain a stumbling block.
Recent publications demonstrate significant interest in the microfluidic research community in
exploring the advantages of centrifugal microfluidics for diagnostics in developing countries [20–22].
In this paper, we have distinctively captured the infrastructural and technological challenges and the
diagnostic needs in EPOCT that can transform centrifugal microfluidics and make it suitable not only
for applications in POCT but also EPOCT. This paper provides an overview of the present and future
diagnostic needs in extreme settings in Section 2. A general construction and setup of centrifugal
microfluidic devices are given in Section 3, followed by a few centrifugal microfluidic based IVD
tests according to their biological relevance. Section 4 describes the design challenges for centrifugal
microfluidics in different healthcare infrastructures in developing countries, with particular attention
to EPOCT.
2. Evolving Diagnostic Needs in Resource Limited Settings
To understand the diagnostic needs in resource limited settings, a clear understanding of the
types of diseases and their effect on life expectancies is mandatory. The United Nations (UN) and
other organizations have been effectively monitoring the disease burden and trying to achieve specific
goals that have been set to improve the health of the population in developing countries and negate
the imbalance in healthcare—one such initiatives being the UN’s Millennium Developmental Goals
(MDGs) [23]. The MDGs have helped to promote the development of new POCT technologies in
the last 10–15 years; these new technologies have performed well in challenging environments and
have improved life expectancies for people living in developing countries. For instance, the mortality
rate of children less than five years old has declined by more than half in Sub-Saharan Africa [24].
Diagnostics was a critical tool for achieving these goals and will remain so for future endeavors in
global heath. One of the MDGs concerns combating diseases such as HIV, malaria, and tuberculosis [22].
This initiative has benefited greatly from POCT devices, with LFS assisting in the diagnoses for millions
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of people in limited resource settings, who could then initiate appropriate treatment at early disease
stages, such as antiretroviral (ART) therapy.
Between 1990 and 2013, life expectancy significantly increased in developing countries in Africa,
Asia, and Latin America, as depicted in Figure 1. However, Figure 1 also illustrates the existing burden
of communicable diseases like HIV, tuberculosis, diarrhea, and other neglected tropical diseases
(NTDs), which remain a major cause of death among children and adults [25]. Various studies have
shown that early diagnosis using LFS platforms benefits disease prevention and treatment and also
lowers the risk of transmission; nonetheless, the lack of effective quantitative tools may lead to new
problems in the near future.
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Figure 1. Life expectancies at birth in 1990 and 2013 for both sexes and different causes of life expectancy 
variation in different regions [26]. 
Diagnostic tools like LFS have aided this transformation. Even today, LFS is used as the first line 
of diagnosis, enabling patients to receive immediate treatment [27]. However, current diagnostic needs 
have evolved. Compromises in diagnosis have resulted in larger complications including medication 
errors, drug resistant diseases, etc. At present, many patients in African and Asian countries contract 
drug resistant strains of disease causing microbes. This has not only raised the need for new drugs and 
diagnostic technologies but remains a global epidemic threat [28,29]. For example, viral load testing is 
an important prognostic tool for patients subjected to ART; this requires a sensitive diagnostic 
procedure generally performed in a centralized laboratory or hospital. The lack of this type of 
quantitative diagnosis in remote settings is a huge challenge to rural healthcare efficacy [30]. 
The UN has announced revised pledges to deliver good health, referred to as the Sustained 
Developmental Goals (SDGs). Among the SDGs’ many ambitious goals, the key area that can be 
bridged with EPOCT is to end diseases like AIDS, malaria, tuberculosis, and other NTDs by  
2030 [31]. The prevalence of such diseases is very high in extreme settings, and medication errors in 
these settings is a common difficulty that results in complications like drug resistance resulting in 
treatment failure. Realistically, improved diagnostic tools are needed in these settings to achieve the 
SDGs. Affordable technological health interventions like vaccines and drugs have made a significant 
impact in the past, but new challenges demand precise diagnosis for lower rates of infection. LFSs are 
used extensively in frontline diagnosis, but diseases that are near elimination require molecular level 
diagnostics in EPOCT [30]. From Figure 1, it is seen that non-communicable diseases are also increasing 
in developing countries, which also indicates a need for platform-based technologies. Integrated systems 
using centrifugal microfluidic technologies are ideally suited to current demands, and effective 
quantitative EPOCT systems could be delivered if such systems are based on a clear understanding of 
the end user’s needs and relevant system functions. 
Figure 1. Life expectancies at birth in 1990 and 2013 for both sexes and different causes of life expectancy
variation in different regions [26].
Diagnostic tools like LFS have aided this transformation. Even today, LFS is used as the first line
of diagnosis, enabling patients to receive immediate treatment [27]. However, current diagnostic needs
have evolved. Compromises in diagnosis have resulted in larger complications including medication
errors, drug resistant diseases, etc. At present, many patients in African and Asian countries contract
drug resistant strains of disease causing microbes. This has not only raised the need for new drugs
and diagnostic technologies but remains a global epidemic threat [28,29]. For example, viral load
testing is an important prognostic tool for patients subjected to ART; this requires a sensitive diagnostic
procedure generally performed in a centralized laboratory or hospital. The lack of this type of
quantitative diagnosis in remote settings is a huge challenge to rural healthcare efficacy [30].
The UN has announced revised pledges to deliver good health, referred to as the Sustained
Developmental Goals (SDGs). Among the SDGs’ many ambitious goals, the key area that can be
bridged with EPOCT is to end diseases like AIDS, malaria, tuberculosis, and other NTDs by 2030 [31].
The prevalence of such diseases is very high in extreme settings, and medication errors in these settings
is a common difficulty that results in complications like drug resistance resulting in treatment failure.
Realistically, improved diagnostic tools are needed in these settings to achieve the SDGs. Affordable
technological health interventions like vaccines and drugs have made a significant impact in the past,
but new challenges demand precise diagnosis for lower rates of infection. LFSs are used extensively
in frontline diagnosis, but diseases that are near elimination require molecular level diagnostics in
EPOCT [30]. From Figure 1, it is seen that non-communicable diseases are also increasing in developing
countries, which also indicates a need for platform-based technologies. Integrated systems using
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centrifugal microfluidic technologies are ideally suited to current demands, and effective quantitative
EPOCT systems could be delivered if such systems are based on a clear understanding of the end
user’s needs and relevant system functions.
2.1. Healthcare Infrastructure in Developing Countries
To deliver effective healthcare in developing countries, understanding the disease and diagnostic
needs is not sufficient; one also has to have a detailed understanding of the existing healthcare
infrastructure to determine the exact extent of resource limitations. The various types of clinical
settings in developing countries can be categorized into three major types, as shown in Table 1; urban
health centers or hospitals, primary healthcare centers, and non-clinical settings. Each of these types
has its own limitations in terms of infrastructure [32], referring to supporting equipment, human
resources, and treatment environment in this context.
Table 1. Clinical infrastructure in developing countries in Asia (South Asia, East Asia, Southeast Asia,
Oceania); Africa (Sub-Saharan Africa, North Africa) and Latin America [32–34].
Infrastructure Availability Urban Health Centersor Hospitals (59%)
Primary Healthcare
Centers (27%)
Non-Clinical
Settings (14%)
Clean water O ˆ ˆ
Electricity O ∆ ˆ
Dust free environment O ∆ ˆ
Cold storage O ˆ ˆ
Stable temperature O ˆ ˆ
Trained professional O O ˆ
Internet access O ∆ ˆ
Key: available (O), partially available (∆), unavailable (ˆ). Urban health centers or hospitals are usually
established by the state or the central government and perform most diagnostic testing in their respective
countries. Primary healthcare centers are found in rural areas, and are often connected to the urban hospital, and
are minimally equipped, including, for instance, a microscope for cell counting, a manual or electric centrifuge,
LFSs and reagents for other colorimetric tests. Non-clinical settings can be a patient’s home or a gathering in the
common area of a village or other rural locations where a test is performed.
The extreme settings are comprised of both non-clinical settings (field clinics, mobile health care
units, etc.) and primary healthcare centers in some cases. Despite the infrastructural challenges between
different healthcare settings, the aim for diagnosis remains the same [33]. The unique advantages
of centrifugal microfluidic based POCT devices to be used in urban health centers and centralized
laboratories have been known [4]. All urban health centers or hospitals and major primary healthcare
centers have infrastructure to operate portable POCT devices capable of detecting a disease, either
quantitatively or qualitatively, [15]. Cepheid’s Genexpert and Malaria LFS are a few examples of such
POCT devices. Table 1 shows that, in non-clinical settings, there is no infrastructure to support any
kind of clinical procedure, and the little infrastructure available relies on semi-trained professionals,
unreliable electricity, limited or no internet connectivity, and lack of clean environments. Such harsh
conditions define the extreme settings that demand EPOCT.
Though EPOCT is not well defined and is an uncommon term, we have distinguished between the
two here for a better understanding. In extreme settings, healthcare is accessed through a community
health worker who performs testing at a patient’s house or at a temporary or semi-permanent
healthcare facility in a remote village or a mobile health unit [32]. Figure 2 shows the differences in
the types of devices used in POCT and EPOCT settings based on the available infrastructure in these
settings. Recent reports suggest that these suggested diagnostic procedures need to be verified against
a gold standard diagnostic procedure before medication is administered, but in reality, this does not
occur [35]. Alarming rates of drug resistant strains of malaria, tuberculosis, and mixed infections
cannot be diagnosed in extreme settings [28]. Primary healthcare infrastructure has improved in recent
years, but has not reached its full potential [36]. Another area of focus in healthcare infrastructure
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development is healthcare data storage and retrieval using server- or cloud-based systems for screening
and monitoring [37].Micromachines 2016, 7, 32 5 of 13 
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(G) CareStart Malaria RDT (Access Bio Korea, Inc., Seoul, Korea); (H) Alere Determine HIV-1/2
Ag/Ab Combo (AlereTM, Waltham MA, USA); (I) HIV 1/2 STAT-PAK®dipstick Assay (ChemBio
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2.2. I in eveloping Countries
ifferent kinds of devices are used for IVD in developing countries, depending on the
infrastructure in the healthcare setting. Figure 2 shows several examples of diagnostic devices currently
approved by the World Health Organization (WHO) for use in developing nations [38,39]. These
devices can be laboratory grade devices for clinical settings, relatively small devices for POCT settings,
or very simple and easy to use devices for EPOCT settings.
Laboratory grade devices such as the flow cytometer and molecular diagnostic device are available
in a centralized laboratory or hospital; these devices can perform complex diagnosis and occupy a large
space. These devices also demand specific conditions such as temperature-controlled environments,
uninterrupted power, trained operators, etc. POCT devices are used in settings with minimal resources
and are effective for repetitive diagnostic procedures in specific tests or biological applications in
primary healthcare settings. EPOCT settings lack any of the above resources.
Stringent quality criteria specific to each of these settings are regulated by the WHO because
almost 68% of the countries in these regions lack any regulations [40]. The WHO periodically releases
an updated list of prequalified diagnostic devices once they are tested and approved for use in
healthcare settings in developing countries. This quality assurance has helped to maintain good quality
in diagnostic products and remove clinically unfit devices [41]. The WHO has prequalified diagnostic
proce ures for high bur en iseases like I , alaria, an the hepatitis virus to the greatest extent
possible, an they have also helpe in eveloping iagnostics for s. he eval ate a
or T test using the ASSURED benchmark (affordable, sensitive, specific, user-friendly, rapi
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and robust, equipment-free and deliverable to end users). Every test used in extreme point of care or
resource limited settings is evaluated using this criteria [42].
Figure 2 shows examples of IVD devices arranged according to the healthcare infrastructure.
The diagnostic devices on top are capable of handling large sample numbers and a variety of tests are
used in clinical settings. The middle row shows the POCT devices used to perform specific tests in
primary healthcare settings, and the bottom row shows LFSs used in EPOCT settings. EPOCT cannot be
deemed completely successful until certain outstanding challenges have been resolved. For example, in
the case of malaria, rapid diagnostic tests (RDT) cannot detect multi-parasite infections [43], and it has
been reported that that in South Africa, only 69% of patients with HIV receive periodic laboratory-based
CD4 counts [44]. Recent reports have indicated that RDT and LFS may not have the appropriate
sensitivity for testing and monitoring certain emerging diseases, and experts have therefore reported
the need for alternative technologies that can assure sensitive and selective diagnosis for a particular
disease and provide results during a clinic visit or within a reasonable waiting time [33]. POCT devices
such as Samba II and Pima CD4 tests are better technologies but are still considered too bulky and
ineffective for EPOCT. Several other diseases also require a quantifiable diagnostic technology for
EPOCT settings [37].
3. Centrifugal Microfluidic-Based IVD
This section focuses on centrifugal microfluidic-based systems for IVD applications. Section 3.1
describes the instrumentation and operation of a commercially available centrifugal microfluidic
system, and Section 3.2 discusses clinical applications of the system described in Section 3.1, which
has been tested for adaptability in POCT settings and found to be suitable for applications including
clinical chemistry, immunoassays, and nucleic acid tests.
3.1. Instrumentation and Operation of Centrifugal Microfluidic Systems
Centrifugal microfluidic systems consist of two major components: the disc and the device,
generally a single rotor equipped with simple peripherals. The centrifugal microfluidic device uses
the same principle of centrifugal force as bulkier centrifuges. This force coupled with the microfluidic
technology helps to reduce the sample volume, resulting in a faster reaction time and also enabling
elimination of the external pumping sources. Centrifugal pumping is used to move the fluids, which
is radially outward from the center, and the movement from one chamber to the other is controlled
by microstructures. Rotational speed, connected channel dimensions, location of the fluidic chamber,
and viscosity of the fluid determine the flow rate in the channels. Complex microfluidic device
operations such as mixing, separation, volume metering, aliquoting, flow switching, and valving
are all possible on the single polymer disc, which has embedded within it the complete microfluidic
architecture. The disc is fabricated from thermoplastic materials such as polycarbonate, polymethyl
methacrylate, or cyclic olefin copolymer; hence, the cost per test can be significantly reduced relative
to other IVD techniques [45,46]. Moreover, the transparent optical property of these materials allows
direct visualization of the process, and direct optical detection on the disc.
The instrumentation for centrifugal microfluidics includes a rotor with an adaptor that fits the disc,
and simple peripherals such as laser diodes, infrared lamps, magnets, and LEDs. These peripherals
facilitate advanced operations on the disc, including valve actuation on demand, heating of the disc,
manipulation of the magnetic field, and detection of optical signals, to integrate and automate more
complex reactions. The automation of assays with these simple instruments render it an ideal candidate
for POCT and EPOCT applications.
3.2. Clinical Applications
IVD can be broadly classified into three areas: clinical chemistry which identifies electrolytes,
minerals, and protein concentrations in a given biological fluid; immunoassays which use antibodies
to detect disease or disorders; and nucleic acid tests that are used when diagnostics demand very
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high precision and sensitivity. The commercially available IVD centrifugal microfluidic devices in
Figure 3 can perform these complex biological applications in the “sample to answer” manner. These
devices can be applied to perform individual applications such as blood chemistry measurements,
lipid profiling, virology, etc.Micromachines 2016, 7, 32 7 of 13 
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t detect both communicable and non-communicable diseases, and are therefore in high demand in
developing countries. Immunoassays involve several sequential steps, including blood separation,
target and antibody incub ti , washing, and detection. Therefore, robust a d accurate microfluidic
flow control is require for full integration. The company Gyros has provided first generation
commercialized centrifugal microfluidic devices for immunoassay applications. In the Gyros devices,
a hydrophobically treated region e able sequential flow co trol, and an injection-molded disc allows
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Micromachines 2016, 7, 32 8 of 14
in a centralized laboratory because it does not perform plasma separation and because a delicate robotic
liquid handler system is required to introduce the reagents. Samsung Electronics and Biosurfit provide
more appropriate centrifugal microfluidic devices for immunoassays in POCT settings. In these
devices, once blood is injected into a disc, the operating system performs an automated immunoassay
and detects the result a few minutes later. The Samsung and Biosurfit systems are designed to detect
cardiac protein biomarkers; however, they can be repurposed for the detection of other proteins, as is
needed in developing countries.
3.2.3. Nucleic Acid Tests
Nucleic acid tests facilitate the detection of a target molecule at the molecular level and have thus
become an important method for the detection of many diseases. Compared to the other two IVD
techniques, full integration of nucleic acid tests in commercially available centrifugal microfluidic
devices remains challenging. It requires a robust and precise microfluidic network because the detection
of nucleic acids often requires a large sample volume and the assay consists of a complex series of
steps, including sample concentration, nucleic acid extraction, target purification, amplification,
and detection. In addition, a precise and accurate heating source is a necessary system component
because the amplification step requires preventing reagent evaporation. For this reason, no centrifugal
microfluidic device has yet integrated the entire nucleic acid detection process. Toward this objective,
Focus Diagnostics (Cypress, CA, USA) provides a universal disc for nucleic acid amplification and
detection. In addition, fast and accurate thermocycling for the amplification step can be achieved
with an infrared heater and disc body rotation for effective cooling. Moreover, a few companies are
currently preparing the products for simplified nucleic acid analysis [47,48].
4. Centrifugal Microfluidic Systems for EPOCT
4.1. Opportunities of Cenfrifugal Microfluidics for EPOCT
Design and development of diagnostic devices for use at the extreme point of care is not the
same as compared to clinical point-of-care. For an extended time period, the diagnostic technologies
developed for use in developing countries were mostly a modified of existing diagnostic technologies
in use in the developed world. From our understanding of healthcare systems in resource limited
settings and insights gleaned from recent reports on diagnosis in extreme settings, we believe an
inclusive understanding is required to rightly distinguish POCT from EPOCT needs. Healthcare
infrastructure-dependent requirements for biomedical devices are described in Table 2. Most of
lab-on-a-chip can meet several requirements such as low sample volume, easy operation, and fast
process time. Above all, centrifugal microfluidics can be distinguished with other platforms since they
enable a real sample-to-answer system for the user including the sample purifications. Many biological
samples like saliva, urine, and blood need sample purification before the utilization for assays. It is
well known that biofluids contain many inhibitors that can cause inaccurate assay results. The simplest
method of sample purification is centrifugal force induced separation and most of the chip based
microfluidics studies rely on centrifugation of samples before the introduction to their chip. However,
this crucial step in the process can be easily be integrated onto centrifugal microfluidic system, and it
allows for the realization of a real “sample-to-answer” system for the end user. It has already been
validated that sample preparation for various fluids can be integrated on centrifugal microfluidic
systems [49–53]. Nevertheless, to the best of our knowledge, there are no centrifugal microfluidic
devices currently available for use in EPOCT settings. Previous reports of lab-on-a-chip and LFS
devices were used to formulate the EPOCT requirements shown in Table 2 [34,37,54]. Technological
developments required for the realization of centrifugal microfluidic devices that can be used in
EPOCT conditions and its supporting instruments are explained in next section.
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Table 2. Healthcare infrastructure-dependent requirements for biomedical devices [34].
Healthcare Setting Urban Health Centers or Hospitals Primary Healthcare Centers Non-Clinical Settings
Device used Non-POCT POCT EPOCT
Sample type All kinds of samples (Venous blood,saliva, sputum, urine, nasal fluid, etc.)
Minimally invasive samples
(Finger prick blood, urine,
saliva, etc.)
Minimally invasive samples
(Finger prick blood, urine,
saliva, etc.)
Sample volume High (>1 mL Blood) Low (<10 µL Blood) Low (<10 µL Blood)
Sample preparation Manual/Automatic Semi-automatic Automatic
Sampling Size Many One ~ Few One
Existing laboratory equipment Advanced Simple (Centrifuge, lightmicroscope, etc.) None
Device footprint Large Medium Hand-held
Power supply Normal Battery/normal Battery
Operation difficulty Low ~ High Medium Low
Processing time Fast/moderate Fast Fast
Usage Heavily used Minimally used Used on demand
Durability Low Medium High
Device cost High Medium Low
Consumable cost Low ~ High Low Low
Diagnostics Screening, Quantification Screening, Quantification Screening, Quantification
Medical data storage Local, Cloud Local, Cloud Cloud
4.2. Challenges of Cenfrifugal Microfluidics for EPOCT
4.2.1. Disc Requirements
EPOCT settings have no infrastructure to support clinical grade diagnosis, and the disc must
therefore be designed to meet these unique EPOCT demands. Centrifugal microfluidic discs are
commonly described as fully integrated; however, a fully integrated disc to be used in EPOCT settings
should have different characteristics as mentioned in Table 2. In EPOCT settings, the cost per test is a
major challenge; in a disc, there are two cost factors, the disc and the biological reagents used for the
assay. Novel cost effective fabrication methods have been reported in recent years and it is advisable
to apply the best possible solution to have the lowest possible cost per test. Developing an inexpensive
disc manufacturing technique would further reduce the overall cost of the system. Recent reports on
inexpensive fabrication techniques appear promising [48,49]; however, the fabrication of electrodes,
valves, heating elements, etc., on the disc can increase the cost of the device, and large scale fabrication
of fully functional discs at minimal cost remains as a challenge.
In POCT settings, diagnostic procedures are generally performed by healthcare workers, whereas
in EPOCT settings, fewer personnel with significantly less training are deployed to implement care.
Therefore, EPOCT systems need to be a foolproof system that functions like a ‘sample in answer out’
system, which does not require any manual execution of intermediate steps. This is ideal in EPOCT
settings. In extreme settings, the samples are limited to saliva, urine, nasal fluid, tear drops, and blood
(by finger prick and not by syringe) to avoid complication and contaminations; therefore variation in the
samples is common and field samples must be used to standardize the testing procedure. Recent reports
show the sensitivity and specificity of the test needs to be evaluated as clinical decisions are made
based on test results [33]. Because of the low sample volumes in EPOCT settings, an appropriately
simplified sample collection system, specific to each biological fluid, should be integrated in the
diagnostic system. For example, a capillary based sample loading inlet on a disc would be ideal for
collecting blood samples, direct swab inlet ports on disc for saliva samples will make a difference.
Temperature variations have been constantly reported as the major challenge as it directly affects
the sensitivity of reagents and sensing elements, and therefore proper precautions must be taken when
selecting the biological reagents and sensing elements for EPOCT settings. For example, aptamers
can be used as stable sensing elements, and similarly, enzymatic reagents can be lyophilized. Lack of
proper waste management in EPOCT settings are another concern, and hence the waste chamber in
the disc should be filled with disinfectant to prevent the spread of disease. Lastly, the discs must be
able to be carried conveniently in large numbers so they can be transported along with the device.
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4.2.2. Supporting Instruments
Although the simplicity of centrifugal instruments make them ideal candidates for POCT, only
with certain revisions can they be implemented as a successful EPOCT device. EPOCT settings
place unique demands on the instruments in areas of cost, power, data storage and retrieval, design,
robustness and low maintained. Affordability is a broad term used for specifying the cost of the
instrument in most of the literature. Instruments like centrifugal microfluidic devices which can
perform a range of diagnosis have a good cost vs. benefit ratio. From recent recommendations for HIV
diagnosis, the cost of the instruments stays affordable when it is less than US$ 500 per machine [55].
Most of the EPOCT settings lack uninterrupted power supply and hence the instrumentation design
should be such that it can be operated without an external power source or solar powered. The
supporting instruments should consist of minimal components, as these devices will not only be
transported to remote locations, but also because minimal components will result in a user friendly
design that will assist the end user, who will usually not be highly trained. Along with ease of transport,
durability is another major requirement of EPOCT designs. Hand-held devices and others with minimal
footprints and compact systems would be ideal for use in EPOCT settings. The instrumentation
should be self-sustaining in terms of power because of the lack of reliable power supplies in EPOCT
settings; therefore, devices that are battery operated and consume little power are preferred. The total
turnaround time from sample to answer should also be as low as possible, which is a primary reason
for the popularity of LFS and RDT techniques. Furthermore, because the device must be transported,
simple built-in detectors should be used in centrifugal microfluidic systems, such as has recently been
reported with the use of DVD and Blu-ray lasers for the detection purpose.
The overall strategy for developing an EPOCT centrifugal microfluidic device relies on a medium
to low cost device with a low cost disc that can store reagent and is fully integrated. The detection
technique should be selected to leverage the use of the instrument for the widest possible range of
biological applications. Electrochemical detection and absorbance offer low power, low cost, and high
sensitivity detection methods, well suited to the demand. The lack of trained professionals in EPOCT
settings demands a fully automated sample-to-answer system with a user friendly interface. Once the
sample is inserted, an automated spinning profile should be able to sequentially process the sample
and provide a readout. The disposal of the processed sample should be safe, which can be achieved
by storing the waste inside the disc to prevent contamination due to handling [34]. Improvements in
health information technology have enabled better data connectivity in these systems, and therefore
the device should have network connection capability, either directly or via a mobile phone interfaced
with the device [30]. Lastly, it has recently been reported that collaborating with local partners and
adopting a patient-centered approach will yield more successful functionality of system designs [15].
Even though a handful of centrifugal technologies are available with the POCT platform, there
are no centrifugal microfluidic devices currently available for use in EPOCT settings. As distinguished
and defined in this paper, EPOCT conditions will bring new challenges, both for researchers and
companies who have interest in these segments. As illustrated, centrifugal microfluidics has shown
advantages over other microfluidics and LFs technology. The advantages like cost, compactness,
complexity free and the wide spectrum of biological techniques that can be performed positions
centrifugal microfluidic systems as forerunners in the race to meet challenging EPOCT requirements
As advantageous as it is in its current form, it still meets the requirements for a perfect EPOCT and
needs improvement in areas that we have discussed above. We have discussed the suggestions as
preliminary directions for improvement; as demands evolve; the technology should be able to able to
bridge the gap and meet EPOCT needs.
5. Conclusions
A review of centrifugal microfluidic systems for use in EPOCT settings has been presented,
and the evolving diagnostic needs of developing countries have been discussed. Various centrifugal
microfluidic devices that have been developed and commercialized were discussed and the key
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considerations for designing and evaluating EPOCT centrifugal microfluidic devices have also been
presented. As identified in this review, diagnostic devices designed for low and middle income
countries require a different approach than is applied to standard clinical practice. The centrifugal
microfluidic systems currently used in POCT settings cannot be directly incorporated into EPOCT
settings. Based on these recommendations, the unique requirements of EPOCT settings can be
integrated onto the centrifugal microfluidic disc and the supporting instrumentation. The challenges
facing EPOCT are significant, and the opportunities offered by centrifugal microfluidic diagnostic
devices are therefore considerable. It can thus be stated that, if the above mentioned recommendations
were to be considered and integrated into existing centrifugal microfluidic devices, they could be made
ready to use in EPOCT settings.
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